Novavax, Inc.
NASDAQ: NVAX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Charles Jacobs
- Employees
- 952
- Headquarters
- Gaithersburg, United States
- IPO year
- 1995
- Market cap
- $1.5B
- Website
- https://www.novavax.com
Loading NVAX…
Loading profile data…Frequently asked questions about NVAX
What does Novavax, Inc. (NVAX) do?
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase...
Where does NVAX trade?
Novavax, Inc. (NVAX) trades on the NASDAQ Global Select.
What sector is NVAX in?
Novavax, Inc. (NVAX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Novavax, Inc.?
John Charles Jacobs is the chief executive officer of Novavax, Inc. (NVAX).
Where is Novavax, Inc. headquartered?
Novavax, Inc. is headquartered in United States.
Does NVAX pay a dividend?
Novavax, Inc. (NVAX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NVAX go public?
Novavax, Inc. (NVAX) completed its initial public offering in 1995.